Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment

Chen Xu; Yalan Liu; Dongxian Jiang; Xiaowen Ge; Jie Huang; Jieakesu Su; Xue Zhang; Shaohua Lu; Yuan Ji; Jun Hou; Tianshu Liu; Yingyong Hou

doi:doi:10.18632/aging.102415

← Back

Research Paper Volume 11, Issue 22 pp 10052—10060

Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment

Figure 2. Survival analysis of both cohorts. (A) The mPFS of the two cohorts showed no statistical difference (10.5 months (95%CI 6.4-14.6) vs 8.0 months (95%CI 3.2-12.8)) (P=0.689). (B) The mOS of the two cohorts did not show statistical difference (23.3 months (95%CI 12.1-34.5) vs 20.0 months (95%CI 10.1-29.9)) (P=0.690).